437 related articles for article (PubMed ID: 23395904)
1. Ubc9 acetylation modulates distinct SUMO target modification and hypoxia response.
Hsieh YL; Kuo HY; Chang CC; Naik MT; Liao PH; Ho CC; Huang TC; Jeng JC; Hsu PH; Tsai MD; Huang TH; Shih HM
EMBO J; 2013 Mar; 32(6):791-804. PubMed ID: 23395904
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of K65 acetylation-induced attenuation of Ubc9 and the NDSM interaction.
Naik MT; Kang M; Ho CC; Liao PH; Hsieh YL; Naik NM; Wang SH; Chang I; Shih HM; Huang TH
Sci Rep; 2017 Dec; 7(1):17391. PubMed ID: 29234076
[TBL] [Abstract][Full Text] [Related]
3. An extended consensus motif enhances the specificity of substrate modification by SUMO.
Yang SH; Galanis A; Witty J; Sharrocks AD
EMBO J; 2006 Nov; 25(21):5083-93. PubMed ID: 17036045
[TBL] [Abstract][Full Text] [Related]
4. Ubc9 acetylation: a new route for achieving specificity in substrate SUMOylation.
Yang SH; Sharrocks AD
EMBO J; 2013 Mar; 32(6):773-4. PubMed ID: 23395903
[TBL] [Abstract][Full Text] [Related]
5. MEL-18 interacts with HSF2 and the SUMO E2 UBC9 to inhibit HSF2 sumoylation.
Zhang J; Goodson ML; Hong Y; Sarge KD
J Biol Chem; 2008 Mar; 283(12):7464-9. PubMed ID: 18211895
[TBL] [Abstract][Full Text] [Related]
6. Site-specific inhibition of the small ubiquitin-like modifier (SUMO)-conjugating enzyme Ubc9 selectively impairs SUMO chain formation.
Wiechmann S; Gärtner A; Kniss A; Stengl A; Behrends C; Rogov VV; Rodriguez MS; Dötsch V; Müller S; Ernst A
J Biol Chem; 2017 Sep; 292(37):15340-15351. PubMed ID: 28784659
[TBL] [Abstract][Full Text] [Related]
7. Structural insights into the regulation of the human E2∼SUMO conjugate through analysis of its stable mimetic.
Goffinont S; Coste F; Prieu-Serandon P; Mance L; Gaudon V; Garnier N; Castaing B; Suskiewicz MJ
J Biol Chem; 2023 Jul; 299(7):104870. PubMed ID: 37247759
[TBL] [Abstract][Full Text] [Related]
8. In vitro modification of human centromere protein CENP-C fragments by small ubiquitin-like modifier (SUMO) protein: definitive identification of the modification sites by tandem mass spectrometry analysis of the isopeptides.
Chung TL; Hsiao HH; Yeh YY; Shia HL; Chen YL; Liang PH; Wang AH; Khoo KH; Shoei-Lung Li S
J Biol Chem; 2004 Sep; 279(38):39653-62. PubMed ID: 15272016
[TBL] [Abstract][Full Text] [Related]
9. Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation.
Park S; Stanfield RL; Martinez-Yamout MA; Dyson HJ; Wilson IA; Wright PE
Proc Natl Acad Sci U S A; 2017 Jul; 114(27):E5335-E5342. PubMed ID: 28630323
[TBL] [Abstract][Full Text] [Related]
10. SUMO modification of Akt regulates global SUMOylation and substrate SUMOylation specificity through Akt phosphorylation of Ubc9 and SUMO1.
Lin CH; Liu SY; Lee EH
Oncogene; 2016 Feb; 35(5):595-607. PubMed ID: 25867063
[TBL] [Abstract][Full Text] [Related]
11. Is Transthyretin a Regulator of Ubc9 SUMOylation?
Wieczorek E; Kędracka-Krok S; Sołtys K; Jankowska U; Hołubowicz R; Seliga J; Ożyhar A
PLoS One; 2016; 11(8):e0160536. PubMed ID: 27501389
[TBL] [Abstract][Full Text] [Related]
12. Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain inhibits E1 Cys domain enzymatic activity.
Truong K; Lee TD; Chen Y
J Biol Chem; 2012 May; 287(19):15154-63. PubMed ID: 22403398
[TBL] [Abstract][Full Text] [Related]
13. Enhanced SUMOylation of proteins containing a SUMO-interacting motif by SUMO-Ubc9 fusion.
Kim ET; Kim KK; Matunis MJ; Ahn JH
Biochem Biophys Res Commun; 2009 Oct; 388(1):41-5. PubMed ID: 19635459
[TBL] [Abstract][Full Text] [Related]
14. SUMOylation of the transcription factor ZFHX3 at Lys-2806 requires SAE1, UBC9, and PIAS2 and enhances its stability and function in cell proliferation.
Wu R; Fang J; Liu M; A J; Liu J; Chen W; Li J; Ma G; Zhang Z; Zhang B; Fu L; Dong JT
J Biol Chem; 2020 May; 295(19):6741-6753. PubMed ID: 32249212
[TBL] [Abstract][Full Text] [Related]
15. Both conditional ablation and overexpression of E2 SUMO-conjugating enzyme (UBC9) in mouse pancreatic beta cells result in impaired beta cell function.
He X; Lai Q; Chen C; Li N; Sun F; Huang W; Zhang S; Yu Q; Yang P; Xiong F; Chen Z; Gong Q; Ren B; Weng J; Eizirik DL; Zhou Z; Wang CY
Diabetologia; 2018 Apr; 61(4):881-895. PubMed ID: 29299635
[TBL] [Abstract][Full Text] [Related]
16. The UBC9 E2 SUMO conjugating enzyme binds the PR-Set7 histone methyltransferase to facilitate target gene repression.
Spektor TM; Congdon LM; Veerappan CS; Rice JC
PLoS One; 2011; 6(7):e22785. PubMed ID: 21829513
[TBL] [Abstract][Full Text] [Related]
17. Enhanced detection of in vivo SUMO conjugation by Ubc9 fusion-dependent sumoylation (UFDS).
Niedenthal R
Methods Mol Biol; 2009; 497():63-79. PubMed ID: 19107411
[TBL] [Abstract][Full Text] [Related]
18. Sumoylation of human argonaute 2 at lysine-402 regulates its stability.
Sahin U; Lapaquette P; Andrieux A; Faure G; Dejean A
PLoS One; 2014; 9(7):e102957. PubMed ID: 25036361
[TBL] [Abstract][Full Text] [Related]
19. RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation.
Yan J; Yang XP; Kim YS; Joo JH; Jetten AM
Biochem Biophys Res Commun; 2007 Oct; 362(1):132-138. PubMed ID: 17698038
[TBL] [Abstract][Full Text] [Related]
20. Dual role for SUMO E2 conjugase Ubc9 in modulating the transforming and growth-promoting properties of the HMGA1b architectural transcription factor.
Li Y; Lu J; Prochownik EV
J Biol Chem; 2007 May; 282(18):13363-71. PubMed ID: 17350957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
